First-Line Combo Immunotherapy Improves PFS in High TMB Non-Small Cell Lung Cancer – Pharmacy Times
Immuno-Oncology NewsFirst-Line Combo Immunotherapy Improves PFS in High TMB Non-Small Cell Lung CancerPharmacy Times“TMB has emerged as an important biomarker for the activity of immunotherapy. For the first time, this phase III study shows superior … Continue reading
